Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002917130 | SCV003665776 | uncertain significance | Inborn genetic diseases | 2022-12-02 | criteria provided, single submitter | clinical testing | The c.1058A>G (p.H353R) alteration is located in exon 7 (coding exon 7) of the MPL gene. This alteration results from a A to G substitution at nucleotide position 1058, causing the histidine (H) at amino acid position 353 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV005227854 | SCV005866744 | uncertain significance | Congenital amegakaryocytic thrombocytopenia; Essential thrombocythemia | 2025-01-29 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine, which is basic and polar, with arginine, which is basic and polar, at codon 353 of the MPL protein (p.His353Arg). This variant is present in population databases (rs756953598, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with MPL-related conditions. ClinVar contains an entry for this variant (Variation ID: 2331851). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt MPL protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |